RxDoctor Payments Data

Jack Campbell, MD

Urology · Columbia, MONPI 1649633736

Payments from drug & device makers

What this record shows

This record is dominated by grants: $50,000 of the $53,690 with a category attached, or 93.1%. Boston Scientific accounts for 97.4% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2021 at $50,063 and has fallen 97.8% since, to $1,112 in 2025. Among urology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$53,690in general payments, 2019–2025

Across 75 payments — averaging $715.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$52K
  • Coloplast$338
  • Astellas Pharma US Inc$239
  • Calyxo, Inc.$145
  • Endo USA, Inc.$139
  • Medtronic$115
  • plus $441 from 11 others

What the payments were for

  • Grants$50,00093%
  • Travel & lodging$4421%
  • Food & beverage$3,0836%
  • Education$1650%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,690 in reported general payments places this provider in the 95th percentile of 250 urology providers in Missouri.

See all urology providers in Missouri

Medicare billing

Part B allowed, 2024
$119,962
Medicare patients
251
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron23$11,851
Trospium Chloride ErTrospium Chloride14$2,309
Tamsulosin Hcl148$1,466
Sodium Chloride0.9 % Sodium Chloride11$696
Nystatin33$682
Finasteride52$572
Testosterone Cypionate14$554
Trospium Chloride13$543
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$441
Fesoterodine Fumarate ErFesoterodine Fumarate16$400
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim32$174
Doxycycline Hyclate14$167
Oxybutynin Chloride ErOxybutynin Chloride25$155
Oxycodone Hcl34$132
Ciprofloxacin Hcl15$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$239$11,85123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 urology providers in Missouri.

Other urology in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →